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Medulloblastoma is the most common solid primary brain tumor in children. Remarkable 
advancements in the understanding of the genetic and epigenetic basis of these tumors have informed 
their recent molecular classification. However, the genotype/phenotype correlation of the subgroups 
remains largely uncharacterised. In particular, the metabolic phenotype is of great interest because of 
its druggability which could lead to the development of novel and more tailored therapies for a subset 
of medulloblastoma. 
p73 plays a critical role in a range of cellular metabolic processes. We show overexpression of p73 in 
a proportion of non-WNT medulloblastoma. In these tumors, p73 sustains cell growth and proliferation 
via regulation of glutamine metabolism. We validate our results in a xenograft model in which we 
observe an increase in survival time in mice on glutamine restriction diet. Notably, glutamine starvation 
has a synergistic effect with cisplatin, a component of the current medulloblastoma chemotherapy. 







Medulloblastoma (MB) is the most common primary paediatric brain tumor and it is a major cause of 
mortality and morbidity in paediatric oncology (Louis et al. 2007). Current treatment strategies include 
a combination of surgery, radiotherapy and chemotherapy; they have achieved 70-80% 5-year 
survival rates, however recurrence is common and it often proves fatal (Hill et al. 2015). In addition, 
both the brain exposure to ionising radiation and the systemic exposure to chemotherapy agents can 
induce severe side effects leading to mental and physical disability of the affected children. 
MB is a heterogeneous tumor with molecularly defined subgroups which arise from different cerebellar 
progenitor cells, albeit often showing rather similar histological features (Corno et al. 2012). MB have 
recently been classified into four molecular groups namely: WNT Group, Sonic Hedgehog (SHH) 
Group, Group 3 (G3) and Group 4 (G4) (Taylor et al. 2012). The discovery that mutant TP53 plays an 
important role in SHH MB pathogenesis led to the further dissection of the SHH group into a TP53 
wild-type and TP53 mutant subgroups, the latter being associated with a poor outcome (Ramaswamy 
et al. 2015). Emerging evidence suggests that each group may require specific therapeutic strategies 
(Northcott et al. 2012) and recent papers demonstrated that WNT MB had anomalous vascularization 
and show increased haemorrhaging (Phoenix et al. 2016). 
The p53-family comprises three members: p53, p63 and p73 (Boominathan 2010) and its role in 
promoting cell death and senescence has been extensively described. Importantly, p63 plays a 
particular role in the development of the epidermis (Vanbokhoven et al. 2011) and p73 is essential for 
the development of the central nervous system (CNS) (Yang et al. 2000). Indeed, p73 is highly 
expressed in the hippocampus, cortex and cerebellum during embryonic stages of CNS development; 
its expression then decreases after birth and it is restricted to the neural stem cell (NSC) niches in the 
adult brain (Pozniak et al. 2002). p73-deficient mice show prominent brain malformations and reduced 
NSC proliferation (Talos et al. 2010). Unlike p53, p73 is not lost but rather frequently overexpressed 
in cancer. Accordingly, p73 is overexpressed in MB tumors and cell lines, even though its role in these 
tumors is still unclear (Zitterbart et al., 2007). 
At the molecular level, p73 is transcribed from two different promoters into proteins that either retain 




and induce apoptosis (Zhu et al. 1998), although TAp73 also has distinct transcriptional targets 
(Allocati et al. 2012). In contrast, Np73 displays anti-apoptotic effect (Dulloo et al. 2010). Recent 
studies have shown that p73 plays an important role in the regulation of metabolic pathways. TAp73 
enhances the pentose phosphate pathway flux (Jiang et al. 2013), activates serine biosynthesis 
(Amelio et al. 2014b) and controls glutaminolysis (Velletri et al. 2013). TAp73 regulates the 
mitochondrial respiration by inducting cytochrome c oxidase (Rufini et al. 2012) and its depletion 
results in decreased oxygen consumption and ATP levels, with increased reactive oxygen species 
(ROS) levels. p73 is also a major transcriptional regulator of autophagy (He et al. 2013) and is 
activated when mTOR is inhibited (Rosenbluth and Pietenpol 2009). Consistent with these data, 
TAp73 knockout mice show premature aging and senescence (Rufini et al. 2012). 
Metabolic adaptation has recently emerged as a hallmark of cancer and as a promising therapeutic 
target (Hanahan and Weinberg 2011). Accordingly, highly proliferating cancer cells must adapt their 
metabolism in order to produce enough energy and mass to replicate. The first step of adaptation is 
through enhanced aerobic glycolysis, which allows cells to metabolise glucose to lactate instead of 
pyruvate (Warburg 1956). Aerobic glycolysis in cancer cells is essential for tumor progression and, in 
MB, has been estimated to account for 60% of ATP production (Moreno-Sanchez et al. 2009). 
In addition to the dependency on aerobic glycolysis, cancer cells exhibit other metabolic 
characteristics such as increased fatty acid synthesis and addiction to glutamine. Some cancer cells 
show glutamine addiction regardless of the fact that glutamine is a nonessential amino acid and one 
that can be synthesized from glucose (DeBerardinis and Cheng 2010). Glutamine is used by the 
cancer cells to synthetize amino acid precursors and in maintaining activation of TOR kinase 
(Ahluwalia et al. 1990). Moreover, glutamine is the primary mitochondrial substrate, is required to 
maintain mitochondrial membrane potential and to support the NADPH production needed for redox 
control and macromolecular synthesis (Wise and Thompson 2010). Importantly, MB metabolism 
exhibits a high dependency on aerobic glycolysis and lipogenesis through the activation of hexokinase 
2 and fatty acid synthase (Gershon et al. 2013; Tech et al. 2015). Additionally, MB limit protein 




(Leprivier et al. 2013). This difference between cancer and normal cells, suggests that targeting 
metabolic dependence could be a selective approach to treat cancer patients. 
In this study, we set out to investigate the metabolic pathways regulated by p73 in MB by means of 
genome wide transcriptome and metabolome analysis in MB cell lines and patient-derived MB cells 
with subsequent biochemical and functional validation in vitro and in vivo in a xenograft mouse model. 
 
Results 
TAp73 is overexpressed in MB and controls proliferation in MB cell lines and patient-
derived primary cells 
p73 was reported to be overexpressed in MB (Zitterbart et al. 2007), although it was unclear which 
p73 isoforms were expressed. To clarify this, we analysed RNA-sequence data derived from 240 
clinically-characterised human MB. Significant overexpression of TAp73 was found in G4 and G3 
MB as compared to normal cerebellum with high expression levels found in SHH MB and very low 
levels in WNT MB (Figure 1A). TAp73, Np73 and Np73 isoforms were not significantly 
expressed in MB (Supplemental Fig. S1A). Next, we looked at the expression of p75NTR and GLS-2, 
two-well characterized TAp73 target genes, important for brain development and glutamine 
metabolism respectively (Niklison-Chirou et al. 2013; Velletri et al. 2013). Consistently with the TAp73 
levels, significant up-regulation of GLS-2 was found in the G4 MB, whilst highest expression of 
p75NTR was detected in SHH MB (Figure 1A). Overall, these analyses demonstrate that the most 
aggressive subgroups of MB express high levels of TAp73 mRNA. 
Next, we analysed the expression of p73 in a range of human patient-derived primary MB cells and 
cell lines. We found the highest level in lCb-1299 (primary human G4 MB), intermediate levels in 
primary SHH MB cells (m137 and m692) and DAOY cell line, with no expression detected in UW228-
2 cell line (Supplemental Fig. S1B). We show at the RNA and protein levels that the only isoform 
expressed in MB cells is TAp73, as a single band of 75kDa was detected in the western blot 




m692, DAOY and UW228-2 cells revealed upregulation of all genes in MB cell expressing p73 
(Supplemental Fig. S1D-F), in keeping with the results of the genome-wide analysis on human primary 
tumors (Figure 1A). 
To explore the role of TAp73 in MB, we transiently knocked-down p73 (p73KD) in DAOY, m137 and 
ICb-1299 cells. Western blot and RT-PCR confirmed p73KD in all cells (Supplemental Fig. S1G-H) 
and showed that the levels of the other p53-family members (p53 or p63) were not affected 
(Supplemental Fig. S1G). Silencing p73 strongly reduced cell growth in DAOY, m137 and ICb-1299 
(Figure 1B). Importantly, we observed a 30% reduction in cell proliferation in ICb-1299 cells, where 
only a partial (44% of p73 levels) knockdown could be obtained (Figure 1C-D). 
These results show that p73 is essential for MB cell growth and proliferation. 
TAp73 regulates GLS-2 in MB cells 
p73 regulates the expression of many target genes involved in cell metabolism, DNA repair or 
apoptosis. To dissect the molecular pathways mediating p73's role in MB, we performed a differential 
gene expression analysis in DAOY comparing p73KD cells with control cells at 48h after silencing. 
RNAseq analysis revealed that a large number of genes involved in metabolism and/or stress 
pathways were differentially expressed upon p73KD and unsupervised hierarchical clustering (HCL) 
demonstrated that DAOY p73KD cluster apart from control cells, suggesting that a distinct 
transcriptome-wide gene signature was associated with the silencing of p73 (Figure 1E, genes 
involved in metabolism and Supplemental Fig. S1I, genes involved in stress pathways). Because we 
were interested in identifying genes that are specifically transactivated by p73, we focussed our 
attention on genes that are down-regulated in the absence of p73. 
We selected 14 genes (>1.5 fold change, P < 0.05) for validation as p73 target genes: GADD45B, 
GLS-2, ASL, SFN, PFKM, ACO2, NOS2, PhKA1, NBN, ENO, AKT2, SDHA, CS and RAD50 (Figure 
1E and Supplemental Fig. S1I,J). p73KD was repeated in DAOY cells and expression of the target 
genes were analysed at three different time points 10, 24 and 48h after silencing. We detected an 
early down-regulation (10h after knocked-down) of GADD45B, GLS-2 and ASL (Figure 1F and 




derived primary MB cells expressing p73, the expression of GADD45B, GLS-2 and ASL was assessed 
in lCb-1299 and m137 after p73KD. In agreement with our previous results, we observed an early 
down-regulation of GLS-2 in both cell lines upon p73KD (Figure 1F). GADD45B and ASL were only 
down-regulated in lCb-1299. Importantly, re-expression of a mouse TAp73 rescued the effect of 
p73KD on the expression levels of GADD45B, GLS-2 and ASL, confirming that they were primary p73 
targets in DAOY cells (Figure 1G). Down-regulation of GLS-2 after p73KD was confirmed at the protein 
level in DAOY cells (Figure 1H). 
These results show that GLS-2 is a conserved TAp73 target gene in MB cells derived from non-WNT 
MB subgroups. 
TAp73 is a critical cellular component for mitochondrial bioenergetics in MB cells 
The importance of glutamine as a nutrient in cancer relies on its suitability as a substrate for the 
mitochondrial TCA cycle (Hensley et al. 2013). Since we observed a strong reduction of GLS-2 after 
p73KD, we measured the mitochondria oxygen consumption rate (OCR) as an indicator of the 
mitochondrial function. A functional bioenergetics profile of DAOY p73KD as compared to control cells 
is shown in Figure 2A. We measured the OCR in response to sequential treatment with oligomycin, 
FCCP and rotenone/antimycin A. We observed a strong decrease in the basal respiration, ATP 
production and spare respiratory capacity upon p73KD, which suggested a profound respiratory 
defects after p73KD (Figure 2A). Similar results were obtain after GLS-2KD (Figure 2A and 
Supplemental Fig. S2A). These findings were validated in patient-derived primary MB cells, m137 and 
ICb-1299, where similar results were obtained (Supplemental Fig. S2B-C).  
Next, we performed a stable p73 knockdown (p73sKD) with two different shRNA p73sKD*3 and 
p73sKD*5. The reduction of p73 protein levels in steady state was confirmed by immunoblotting 
(Supplemental Fig. S2D). Importantly, re-expression of GLS-2 in a stable p73 knockdown setting 
(p73sKD*5) rescued the OCR levels (Supplemental Fig. S2E, F, G).  
While assessing whether p73KD induces mitochondrial dysfunction, we observed a strong 
mitochondrial hyperpolarization in DAOY cells upon p73KD (Supplemental Fig. S2H). Because 




glutamine is a precursor of glutathione synthesis (GSH, the major antioxidant within the cells), we 
measured the redox status of DAOY cells upon p73KD or in our stable p73sKD*3, p73sKD*5 or after 
GLS-2KD as assessed by the GSH/GSSG ratio (Figure 2B). A decreased ratio of reduced glutathione 
to glutathione disulfide was observed after p73KD or p73sKD or after siGLS-2, confirming that after 
p73 or GLS-2 knockdown DAOY cells are under oxidative stress. Importantly, this effect was 
completely rescued after GLS-2 overexpression (Figure 2B), indicating that GLS-2 is an important p73 
target gene for balancing the redox status of the cells. 
Since 60% of ATP production in MB cells is generated by aerobic glycolysis (Moreno-Sanchez et al. 
2009), we measured the extracellular acidification rate (ECAR) in DAOY cells upon p73KD (Figure 
2C). The results show a robust decline (50%) in lactate production after p73KD compared with control 
cells in response to oligomycin treatment, suggesting a reduced ability to increase glycolytic flux under 
conditions of increased ATP demand. 
Next, we set out to confirm these results by measuring the kinetic of glucose uptake and lactate 
production in DAOY upon p73KD at different time points. In control cells the levels of glucose 
decreased steadily over time with an increased lactate production observed in parallel; whereas an 
inhibition of glucose uptake and production of lactate was observed after 20h in DAOY p73KD (Figure 
2D-E). Importantly, glucose levels increased in DAOY p73KD, indicating that the lack of TAp73 
induced gluconeogenesis in the longer term. Gluconeogenesis is a common process in tumor cells, 
where cells can derive energy from ketone bodies, which are converted to acetyl-CoA and shunted 
into the TCA cycle. 
Because oxidative phosphorylation and aerobic glycolysis are the two main sources of cellular energy, 
we measured ATP levels in DAOY, m137 and lCb-1299 cells. In line with our previous results, a strong 
reduction in the ATP levels was observed upon p73KD in DAOY, m137 and ICb-1299 cells (Figure 2F 
and Supplemental Fig. S2I). Similar results, were observed upon GLS-2KD (Supplemental Fig. S2I). 
Taken together these data suggest that p73 is essential for the major energy-producing pathways and 





p73 sustains activation of the mTOR pathway by inhibiting AMPK activation in MB 
AMPK plays a role as a master regulator of cellular energy and is activated when cellular ATP levels 
drop and initiates a cellular reprogram that allows the cell to adapt to the energetic stress (Hardie et 
al. 2012). We observed a robust activation of AMPK, as assessed by phosphorylation of its direct 
target acetyl-CoA carboxylase (ACC), in DAOY after p73KD (Figure 2G). An important mediator of the 
AMPK response is the mTOR pathway, which is inhibited by AMPK (Liu et al. 2012). We show here 
inhibition of the mTOR pathway as shown by reduced phosphorylation of its downstream target, the 
protein S6 kinase (S6K) and eukaryotic translation elongation factor 2 (eEF-2), upon p73KD (Figure 
2G). 
mTOR is a nutrient sensor, whereby glutamine and leucine levels stimulate protein synthesis via 
signalling through the mTOR complex. Conversely, mTOR inhibition leads to reduction in the rate of 
the global protein production (Zhao et al. 2015). In order to determine whether p73 supports protein 
synthesis in DAOY cells, we silenced p73 in DAOY cells and then treated for 1h with puromycin. The 
incorporation of puromycin in the newly synthesized proteins was assessed with an anti-puromycin 
antibody. We found reduced protein synthesis of around 50% in DAOY p73KD (Figure 2H and 
Supplemental Fig. S2J). These data suggest that p73 modulate mTOR activation through reduction 
in AMPK activity in MB cells. 
Profound metabolic changes in MB cells after p73KD 
Cellular metabolism is characterized by many parameters including nutrient uptake or metabolite 
secretion rates (Buescher et al. 2015). We measured amino acid levels in the medium of DAOY p73KD 
as compared to controls 48h after silencing. We show that the lack of p73 reduces 14 amino acids 
and increased the levels of 4. Alanine, glutamine and glutamate are the most noticeably reduced 
amino acids (Figure 3A). Interestingly, the main source of carbon skeletons used for gluconeogenesis 
are lactate and the amino acids alanine and glutamine, thus these data are in agreement with our 
previous observation that p73KD induces gluconeogenesis (Figure 2D). 
The four amino acids augmented in the medium are serine, glycine, ornithine and proline (Figure 3A). 




et al. 2014a). Since these amino acids show increased levels in the absence of the p73, it is likely that 
this represents a compensatory effect not directly linked to p73. We confirmed these results by 
measuring the kinetic of serine and glycine production (Supplemental Fig. S3A-B), we observed a 
significant increase in serine/glycine synthesis after 20h of p73KD. Importantly, serine can be used by 
cancer cells for the de novo synthesis of ATP (Maddocks et al. 2016). 
Next, we measured the expression of pyruvate kinase isozymes M2 (PKM2), an enzyme characterized 
by a low affinity to its substrate phosphoenolpyruvate (PEP) which is almost inactive at physiological 
PEP concentrations. High RNA level of PKM2 was observed in DAOY cells after 24 and 48h of p73KD 
(Figure 3B). Importantly, presence of PKM2 will induce accumulation of glycolytic intermediates above 
pyruvate kinase and, therefore, will increase the synthesis of serine/glycine or the pentose phosphate 
pathway flux. 
Following, we used liquid chromatography hyphenated to high resolution mass spectrometry (LC-
HRMS) based untargeted metabolite profiling to study potential differences in the intracellular polar 
metabolome (endogenous molecules with a molecular weight below 1000 Da) in DAOY p73KD as 
compared to controls 48h after silencing. A clear difference between the two conditions was found 
(Figure 3C-D), indicating that silencing of p73 induces a strong difference in the polar metabolites of 
the cells. The absence of p73 in DAOY cells induces a significant reduction of adenosine, malic acid 
and choline, as well as several phospholipids. The reduction in adenosine observed is in agreement 
with the reduction in ATP levels observed after p73KD (Figure 2F and Supplemental Fig. S2I). 
Importantly, we observed a strong reduction in choline and phospholipids (Figure 3E), both of which 
can function as an energy source since they can be degraded to produce acetyl-CoA and the reduction 
in malic acid is in line with our observation that the activity of the TCA cycle was reduced after p73KD. 
Importantly, the levels of cytidine, guanine, guanosine, hypoxanthine, inosine, uridine, phenylalanine, 
indoleacetic acid, N-formyl-L-methionine, 4-phosphopantohenoylcysteine and pyruvic acid were 
significantly (p< 0.05) up-regulated (Figure 3E). We performed a pathway analysis using the web-
based software MetaboAnalyst (www.metaboanalyst.ca). We found that several metabolites were 




observation that after p73KD we have an increase in serine/glycine synthesis, whereby serine can 
contribute to the purine metabolism by providing one-carbon units (Maddocks et al. 2016). 
During gluconeogenesis, lactate and alanine are consumed to produce pyruvate, hence the strong 
reduction in alanine and the increase levels of pyruvate that we observed in DAOY p73KD. Pyruvate 
will be oxidized to feed into the gluconeogenic pathway (Supplemental Fig. S3C).  
In summary, silencing of p73 in DAOY cells induces a profound metabolic alteration in which the cells 
try to compensate for the lack of energy due to reduced glutamine metabolism through a 
compensatory mechanism. Instead, lactate and pyruvate intermediates are utilized to feed into the 
gluconeogenic pathway. This process will allow the cells to produce large amount of serine/glycine 
and synthetize intermediates of the purine pathways and nucleosides probably to synthetize ATP de 
novo. 
TAp73 expression is a biomarker of glutamine addiction in MB cells 
Glutamine is an abundant and versatile nutrient that participates in energy formation, redox 
homeostasis and macromolecular synthesis in cancer cells (Altman et al. 2016). These characteristics 
make glutamine metabolism an appealing target for new clinical strategies. Importantly, some cancers 
display addiction to glutamine despite the fact that glutamine is a non-essential amino acid (Wise and 
Thompson 2010). 
Nutrient deprivation is a strong stress with dire consequences on cell viability and energy status 
(Leprivier et al. 2013). Therefore, we investigated whether removal of the amino acid glutamine or 
serine/glycine or glucose, induced a differential response between medulloblastoma cells expressing 
p73 and those without p73. Firstly, we measured the impact on cell growth after glucose (Glc starv), 
glutamine (Gln starv) and serine/glycine (Ser/Gly starv) starvation. Cell number were recorded in 
DAOY and UW228-2 cultures after 24h under starvation as examples of a p73 expressing and non-
p73 expressing line respectively. In DAOY cells, we observed proliferation arrest under glucose 
starvation, a significant reduction of the cell number under glutamine starvation and no significant 
effect under serine/glycine starvation (Figure 4A). Likewise, the three-starvation conditions were able 




in DAOY cells after glutamine starvation, we hypostatize that this could be due to cell death. To 
validate this results, we measured cell proliferation of DAOY and UW228-2 cells under the three-
starvation conditions. We found that only Gln-starvation induces a robust inhibition of cell proliferation 
in DAOY cells after 15h treatment as assessed by EdU incorporation (Figure 4B-C).  
It was reported that nutrient deprivation induces autophagy (Filomeni et al., 2015), therefore, we 
measured the levels of LC3-II by FACS analysis in DAOY and UW228-2 cells in control medium and 
after 24h under glucose, glutamine or serine/glycine starvation. No increase in LC3-II levels was 
observed (Supplemental Fig. S4A). 
Next, we assessed if glucose, glutamine or serine/glycine was essential for ATP production in DAOY 
and UW228-2 cell lines. Cells were subjected to starvation for 24h followed by measurement of the 
ATP levels (Figure 4C). We show a 96% reduction in the ATP levels in DAOY cells after Gln-starvation, 
while no changes were seen in UW228-2, suggesting that the cell line expressing p73 had a glutamine 
addiction phenotype (Figure 4D). 
p73 protein levels are usually maintained low by rapid proteasome degradation, however DNA 
damage and different stress signals may trigger the stabilization of p73. Therefore, we measured p73 
levels in DAOY cells after 18h under the three-starvation condition (Figure 4E). We observed 
upregulation of p73 only under glutamine starvation. Importantly, Gln-starvation of DAOY cells for 4, 
6 and 8h concomitantly with MG132, a proteasome inhibitor that reduces the degradation of ubiquitin-
conjugated proteins, induced enhancement of the p73 stabilization (Supplemental Fig. S4B). Since 
increased levels of p73 can induce apoptosis (Asher et al. 2005), we measured apoptosis with 
Annexin/PI in DAOY and UW228-2 cells under the different starvation condition. After 36h of starvation 
only DAOY cells under Gln-starvation show a strong apoptosis response (Figure 4F), while UW228-2 
did not show apoptosis under the three-starvation conditions (Supplemental Fig. S4C). 
Next, we challenged DAOY, UW228-2 and the primary G4 cells, lCb-1299, with Gln-starvation or Gln-
starvation plus MG132. We show a strong synergistic effect in inducing cell death in DAOY and lCb-




Subsequent, we analysed the kinetic of glucose uptake and lactate production in DAOY cells in control 
medium and under glutamine starvation. We observed that glucose levels decreased steadily over 
time in DAOY cells in control medium, with an increased lactate production observed in parallel; an 
inhibition of glucose uptake and production of lactate was observed after 20h in DAOY under Gln-
starvation (Supplemental Fig. S4D-E). Importantly, we were unable to detect the induction of 
gluconeogenesis under Gln-starvation condition. Therefore, we measured serine and glycine levels in 
the medium of DAOY cells in control medium or under Gln-starvation condition (Supplemental Fig. 
S4F-G). We observed an initial drop in serine and glycine levels, but at a later time point, 40h, the 
levels were equal to control. These data suggest that under Gln-starvation condition, DAOY cells are 
not able to induce a metabolic reprogramming to allow them to adapt and survive under glutamine 
starvation. 
These data strongly support our hypothesis that expression of p73 predicts a phenotype of glutamine 
addiction in MB cells. 
Synergistic effect of glutamine starvation and cisplatin in MB cells expressing p73 
Cisplatin and etoposide are effective in MB patients (Evans et al. 2009) and, therefore, we treated 
DAOY cells with glutamine starvation in conjunction with two different concentrations of cisplatin or 
etoposide for 18h. Importantly, we found a strong enhancement of the apoptotic effect after Gln-
starvation plus cisplatin while no effect was seen with the Gln-starvation plus etoposide treatment 
(Figure 5A). 
Next, we evaluated the impact on cell proliferation, as assessed by EdU incorporation in lCb-1299 
primary cells treated with Gln-starvation or compound 968 with or without cisplatin for 18h. Compound 
968 is a cell-permeable, inhibitor of GLS-2 which mimic a condition of glutamine starvation. We 
observed that Gln-starvation or compound 968 alone induced 25 or 30% inhibition in cells proliferation 
respectively (Figure 5B and Supplemental Fig. S5A). Importantly, the combination of Gln-starvation 
plus cisplatin or compound 968 plus cisplatin induced a strong synergic effect of 45 to 80% inhibition 




To assess whether p73 was mediating the apoptotic response upon Gln-starvation, we performed a 
stable p73 knockdown (p73sKD*3 and p73sKD*5). A robust apoptosis was observe in DAOY cells 
after Gln-starvation or Gln-starvation plus cisplatin after 30h of treatment (Figure 5C). Importantly, no 
effect was observed under Gln-starvation in both p73sKD cells with only negligible apoptosis observed 
under Gln-starvation plus cisplatin in both p73KD cells. Furthermore, a strong reduction in ATP levels 
was observed in control DAOY cells after Gln-starvation or Gln-starvation plus cisplatin but the effect 
was abolished in DAOY p73sKD (Figure 5D). These data support the conclusion that p73 is an 
important element to mediate apoptosis in MB cells under glutamine starvation. 
To confirm the “glutamine addiction phenotype” in MB primary cells, we evaluated the cell number and 
the ATP levels after treatment with Gln-starvation, cisplatin, Gln-starvation plus cisplatin, 6-Diazo-5-
oxo-L-norleucine (DON, a glutamine antagonist) or DON plus cisplatin in m137 and lCb-1299 human 
primary cells. We demonstrated a synergistic effect resulting in a reduction of cell number only when 
cells expressing p73 were treated with the combination of Gln-starvation plus cisplatin or DON plus 
cisplatin (Figure 5E). Instead, a strong reduction of ATP levels is observed already under Gln-
starvation or DON treatment (Supplemental Fig. S5B), in keeping with MB cells expressing p73 using 
glutamine as a primary source of energy.  
These results confirm the glutamine addiction phenotype of MB cells expressing p73. 
Glutamine starvation induces ROS and DNA damage in MB cells expressing p73 
Nutrient deprivation induce reactive oxygen species (ROS) (Wu et al. 2013) and, therefore, we asked 
if glucose, glutamine or serine/glycine starvation could induce the accumulation of ROS with 
subsequent induction of DNA damage. We starved DAOY and UW228-2 cells of glucose, glutamine 
or serine/glycine for 12h, followed by ROS assessment with the probe H2DCFDA. We observed that 
under the three starvation condition, DAOY and UW228-2 cells underwent a redox imbalance reflected 
by increased ROS levels (Figure 6A), an effect that was prevented by the addition of N-acetyl cysteine 
(NAC) (Figure 6B and Supplemental Fig. S6A). 
We next assessed whether the increased ROS levels induced DNA damage. DNA double strand 




nuclear foci at the sites of damage in DAOY cell nuclei 24h post starvation. Confocal imaging of -
H2AX foci indicated that Gln-starvation induced foci that were more abundant and significantly larger 
in DAOY cells as compared to control cells (Figure 6C-D). Similar findings were not observed after 
glucose or serine/glycine starvation treatment. Furthermore, the combination Gln-starvation plus 
cisplatin induced an accumulation of foci in the nuclei at 10h that were comparable to Gln-starvation 
alone after 24h. This results suggest that cisplatin treatment induce a synergistic effect with Gln-
starvation. 
Next, we measured the redox status with GSH/GSSG ratio, as a marker for oxidative stress, in DAOY 
and UW228-2 cells in control medium and in glucose, glutamine or serine/glycine starvation. We found 
that the levels of GSH/GSSH ratio dropped significantly in DAOY cells under Gln-starvation, less so 
under serine/glycine starvation and not significantly under glucose starvation (Figure 6E). Importantly, 
no effect in GSH/GSSH ratio was observed in UW228-2 cells. 
To confirm this result, we measured NADH levels in these cells under the different starvation 
conditions, because NADH levels are a well-recognized indicator for cellular metabolic homoeostasis. 
In fact, increased ROS level and reduced NADH levels represent a status of metabolic imbalance (Li 
et al. 2016). We show a significant reduction of the NADH levels under Gln-starvation in DAOY cells, 
while no effect was observed in UW228-2 cells (Figure 6F).  
Together these results suggest that MB cells that express p73 show a glutamine addiction phenotype, 
at least in part by maintaining an oxidant detoxification capacity. 
Glutamine restriction diet reduce medulloblastoma tumor growth 
We then set out to validate our in vitro results in an in vivo mouse model of medulloblastoma. Firstly, 
we show that chronic depletion of non-essential amino acid glutamine (glutamine restriction diet) is 
well tolerated in vivo (Supplemental Fig. S7A). Subsequently, ion-exchange chromatography 
confirmed a significant drop in the levels of glutamine and glutamate, but not other amino acids, in the 
cerebellum and in the cerebrospinal fluid (CSF) of mice treated with glutamine restriction diet (Figure 
7A-B and Supplemental Fig. S7B-D). Importantly, high levels of serine were observed in normal 




metabolism for de novo ATP synthesis and survive under Gln-restriction diet. Injection of ICb-1299 in 
the cerebellum of new-born NOD-SCID mice rapidly induced tumors with histological and 
immunohistochemical features of MB (Supplemental Fig. S7E). Animals fed with a Gln-restriction diet 
displayed a significant increase in survival time compared to those mice fed a control diet (Figure 7C). 
Importantly, the combination of Gln-restriction diet with cisplatin (2 and 3 doses) induced a significant 
synergic effect and extended the survival time (Figure 7C). Indeed, we detected a significant reduction 
in cell proliferation (Ki67 staining) with a strong increase in apoptosis (cleaved caspase-3) in the 
animals fed with Gln-restriction diet while being treated with cisplatin as compared to control mice 
(Figure 7D).  
These results are in agreement with our in vitro data where Gln-starvation leads to reduced 
proliferation and increased apoptosis in synergism with cisplatin in MB cells expressing p73. 
Discussion 
Medulloblastoma represent a heterogeneous group of brain tumors with distinct molecular and 
pathological features. Current treatments for MB include surgery, radio- and chemotherapy, which 
induce severe side effects in a substantial proportion of patients. We have focused on elucidating the 
metabolic vulnerabilities of MB for the development of a new therapeutic strategy to minimize the 
adverse effects of the current therapy. 
We show here that TAp73 is over-expressed in a proportion of MB, including aggressive subgroups, 
a finding which confirms and further extends the original description of p73 protein over-expression in 
MB (Zitterbart et al. 2007).  
Numerous evidence suggest that p73 has a well-defined role in cell metabolism and brain 
development (Agostini et al. 2016). However, because of the existence of numerous splice variants 
as well as because of the regulation of protein stability by proteasomal degradation and micro-RNA, 
its precise effect on cellular metabolism is currently ill defined. 
We set out to assess whether p73 regulate any aspect of cell metabolism in human MB and to 
characterize the relationship between p73 status and the sensitivity to glutamine restriction treatment. 




changes by genome wide transcriptome and global metabolite profiling. The global metabolite profiling 
is a novel and powerful approach to gain a comprehensive analysis of small endogenous metabolites 
(Nicholson et al. 1999). Such data can be used to form a hypothesis describing possible metabolic 
alternations due to perturbation of the cellular system (Haggblad Sahlberg et al. 2017). Overall, our 
studies shows for the first time that TAp73 is essential for accurate mitochondrial bioenergetics, at 
least in part by modulating GLS-2 expression, in agreement with previous data in a non-neoplastic 
context (Velletri et al. 2013).  
The role of GLS-2 in tumorigenesis is context specific and regulated by factors that are still 
incompletely characterized (Hensley et al. 2013). GLS-2 is a mitochondrial protein that hydrolyse 
glutamine to glutamate. Following this, glutamate will be used in the cells as a substrate in the TCA 
cycle or for glutathione synthesis. We show that p73KD-induced growth inhibition in MB and it is 
directly linked to reduced mitochondria respiration rates and glycolytic capacity. Notably, our data 
suggest that MB cells expressing p73 may be more dependent on mitochondrial respiration for ATP 
production. Taken together these data suggest that TAp73 plays an essential role in maintenance of 
MB cell energy. 
Cells regulate energy levels through AMPK, which acts as a sensor of the ATP/ADP ratio (Hardie et 
al. 2012). AMPK activation induces metabolic changes leading to ATP renewal with inhibition of ATP 
consumption (Wu et al. 2013). The changes in ATP levels trigger the activation of the energetic stress 
responses (Mihaylova and Shaw 2011). The function of AMPK is partly mediated by mTOR, which 
lies at the heart of a nutrient-sensing signalling network that controls cellular metabolism (Liu et al. 
2012). After p73KD, we observed a strong activation of AMPK with a robust inhibition of mTOR, 
suggesting that p73 maintains the activation of mTOR pathway through modulation of AMPK activity. 
We demonstrate that p73KD induces a robust reprograming of metabolic process, including de novo 
glucose synthesis, also called gluconeogenesis. This process allows cells to synthetize serine/glycine 
and pentose phosphate pathway components from glycolytic intermediates. The role of serine in one-
carbon metabolism to support the methionine cycle is well documented (Meiser et al. 2016) and 
recently it was also implicated in de novo ATP synthesis (Maddocks et al. 2016). After p73KD, we 




contribution to RNA and DNA synthesis. However, because p73KD induces inhibition of cell 
proliferation, it is most likely that the cells are using serine/glycine pathway for ATP generation after 
p73 silencing, as previously demonstrated in colon cancer (Maddocks et al. 2016). 
Over the past forty years, it has become increasingly clear that tumor cells exhibit specific amino acid 
dependency and cells from different tumors were shown to die quickly in vitro following arginine, 
cysteine or glutamine deprivation, whilst normal cells survived (Liu et al. 2015). p53-deficient tumors 
are vulnerable to serine/glycine starvation (Maddocks et al. 2013) although current therapies do not 
fully exploit this major difference between cancer cells and non-neoplastic cells.  
Here, we demonstrate that MB cells expressing p73 are “glutamine addicted”. Glutamine plays an 
important role in supporting tumor growth as it is essential for the synthesis of glutathione, an important 
mitochondrial antioxidant (Amores-Sanchez and Medina 1999). Glutathione is capable of preventing 
damage of different cellular components caused by ROS such as free radicals, peroxides or lipid 
peroxides (Mari et al. 2009). MB growth in vitro is inhibited in p73-expressing cells under Gln-
starvation and it is associated with an abrupt depletion of intracellular ATP. Importantly, MB cells under 
Gln-starvation show DNA damage, even though all three-starvation conditions induce over production 
of ROS. A wealth of literature supports the role of p73 in inducing apoptosis after DNA damage 
(Allocati et al. 2012). We show that only Gln-starvation induces TAp73 stabilization. Indeed, 
combination of Gln-starvation with cisplatin (a chemotherapy agent of choice in MB therapy) induced 
a dramatic apoptotic response possibly because of a mitochondria ROS response known to be 
triggered by cisplatin (Marullo et al. 2013). In keeping with this interpretation, treatment with etoposide 
did not elicit a similar effect. We validated p73's role in inducing apoptosis following glutamine 
starvation through the use of a stable p73 knockout. Crucially, these cells became refractory to 
glutamine starvation. This suggests that any drug inducing p73 stabilization or DNA damage will have 
a synergistic effect with Gln-starvation. 
To validate these results in an in vivo mouse model of medulloblastoma, we generated orthotropic 
xenografts of patient derived MB cells expressing p73 in NOD-SCID mice. Kaplan-Meier analyses 
showed that Gln-restriction diet induces a significant increase in the overall survival rate of the 




(cleavage caspase-3). Importantly, we observed a synergic effect between Gln-restriction diet and 
cisplatin treatment, raising the possibility that glutamine restriction diets could be used as an adjuvant 
treatment for p73-expressing medulloblastoma. 
In summary, we show that p73 support mitochondria respiration in MB via regulation of glutamine 
metabolism. Importantly, we validate the susceptibility to Gln-restriction diet of p73 expressing MB in 
a xenograft model. The findings presented here support the notion that p73 is a marker of glutamine 
addiction in MB tumors and raise the possibility that glutamine restriction diet could be implemented 
to maximize MB growth control while minimizing treatment toxicity. 
Material and Methods 
LC-HRMS based metabolite profiling. The analysis was performed using an Acquity UPLC I-class system 
from Waters (Manchester, UK) coupled to a G2S Synapt Q-TOF equipped with an electro spray ionization (ESI) 
source (Waters). The sample separation was performed on a HILIC-Amide column (1.7 μm, i.d. 2.1x50 mm) 
from Waters and the column temperature was kept at 40°C. 
Extra-cellular amino acid measurement: The medium and cerebellar extracts were centrifuged and the 
supernatant was analysed. For CFS, at least 1L of CFS per animal was extracted. Next, 1L of CSF was diluted 
to 500L with deionized water and analysed. Analysis was performed by ion-exchange chromatography, post 
column derivitisation with ninhydrin and photometric detection. 
Extra-cellular glucose and lactate measurement: Medium from DAOY control and sip73 cells was collected 
a different time points. The medium was centrifuged and the supernatant was analysed with an Accutrend®Plus 
System (Roche) according to the manufacturer’s instructions. 
Measurement of Intracellular ROS: The DAOY and UW228-2 cells were incubated with 5μM C-DCDHF-DA-
AM (Invitrogen) for 30min. ROS fluorescence (emission:∼530nm) was measured by a 200ms-exposure 
(excitation:∼480 nm). 
Xenografts mouse model: All procedures had Home Office approval (Animals Scientific Procedures Act 1986, 
PPL:70/7275). NOD-SCID were divided randomly into two groups (Control diet or Gln-restriction diet), each 




Statistical analysis: All results are expressed as mean values ±SD or ±SEM of at least three independent 
experiments. The unpaired Student’s t test and analysis of variance (one-way Anova) was used to assess 
significant differences between results. P values <0.05 were considered statistically significant. 
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Figure 1. p73 is overexpressed in medulloblastoma and regulates GLS-2 expression. A) Box plot 
representation of TAp73 p75NTR and GLS-2 expression levels (FPKM: fragments per kilobase of transcript 
per million mapped reads) across a cohort of 240 primary MB. Patient number per group are WNT:28, SHH:58, 
G3:59, G4:95, CB:3 ***P<0.001. B) DAOY, m137 and ICb-1299 cells were transiently transfected with scramble 
or sip73 (sip73*1: ID: 2671, sip73*2: ID: 115666). After 48h, cells under different treatments were counted in 
triplicates. For apoptosis assessment (% of cells in SubG1), cells were stained with PI and analysed by FACS. 
C) Confocal microscope images of ICb-1299 scramble cells or sip73*2 after 48h. We assessed cell proliferation 
by EdU incorporation. Size bar=20m. D) Quantification of EdU staining in ICb-1299 scramble cells and sip73*2. 
Columns, mean (n=3) ±SEM. E) Heat map representation of the most significantly up or downregulated genes 
after sip73*1. Genes involved in metabolism were plotted. Genes were identified using MSigDB and plotted to 
highlight differences in expression of 3 z-scores or greater between the two groups (red = relative upregulation, 
blue = relative downregulation). F) MB cells (DAOY, ICb-1299 and m137) were transiently transfected with 
scramble or sip73*1 for 10, 24 and 48h. Columns, mean (n=3) ±SEM; ***P<0.0001. G) DAOY cells were 
transiently transfected with scramble or sip73*1 human or sip73*1 human plus TAp73 mouse for 10 hours. RT-
PCR was performed for TAp73 human, TAp73 mouse, GLS-2, ASL and GADD45B genes. Columns, mean (n=3) 
±SEM; ***P<0.0001. H) DAOY cells were transfected with scramble or sip73*1. Western blot showing p73 and 
GLS-2 protein levels after silencing. GAPDH was used as a loading control. 
Figure 2. p73KD induces mitochondrial defects and activates AMPK signalling. (A) DAOY cells were 
transfected with scramble, sip73 (sip73*1: 2671, sip73*2: 115666) or siGLS-2 (siGLS-2*1: s25941, siGLS-2*2: 
s223735). OCR in response to mitochondrial stress test were recorded to construct functional bioenergetic 
profiles. A minimum of five different samples were analysed for each group;***P<0.0001 (unpaired, two-sided t-
test). A representative experimental data, out of three, is shown. B) Reduced and oxidized glutathione ratio was 
measured in DAOY cells after transient transfection with scramble, sip73*1, sip73*2, siGLS-2*1 and siGLS-2*2 
for 24h. DAOY cells were infected with an empty vector or with shRNA (p73sKD*3 and p73sKD*5) alone or 
transfected with FLAG-GLS-2 expressing vector for 48h. (n=3). Data were mean ± SD. (*P < 
0.01,**P<0.001,***P<0.0001). (C) DAOY cells were transfected with scramble or sip73 (sip73*1: 2671, sip73*2: 
115666). ECAR was measured in response to mitochondrial stress test. A minimum of five different samples 
were analysed for each group;***P<0.0001 (unpaired, two-sided t-test). A representative experimental data, out 
of three, is shown. D-E) DAOY cells were transfected with scramble or sip73*2. After 8h of transfection the 
medium was changed and samples were collected after 6, 20, 30 and 40h. The results show glucose 
consumption (D) or lactate production (E). Columns, mean (n=4) ±SEM;**P<0.001,***P<0.0001. F) DAOY cells 
were transiently transfected with scramble, sip73*1 or sip73*2. After 48h, cells were collected and ATP levels 
were determined. Columns mean (n=4) ±SEM;***P<0.0001. G) DAOY cells were transfected with scramble or 
sip73*1 or sip73*2. After 48h a western blot was performed for ACC, P-ACC, S6K, P-S6K, eEF-2 and P-eEF-2. 
Intensity analysis is shown under each lane, scramble was considered 1. H) DAOY cells were transfected with 
scramble or sip73*1 or sip73*2. After 48h, cells were treated for 1h with puromycin 2.5mg/ml. Next, cells were 
collected and a western blot of lysed cells probed with a primary anti-puromycin antibody. Tubulin was used as 
a loading control. FCCP: Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone. 2-DG: 2-Deoxy-D-glucose. 
Figure 3. p73 regulates metabolic pathways in MB. DAOY cells were transfected with scramble or sip73*1 
(ID: 2671). A) After 48h the medium was collected and amino acid levels were quantified (n=3). B) After 0, 24 
and 48h cells were collected and RT-PCR was performed for TAp73 and PKM2 genes. Columns mean n=3; 
±SEM,***P<0.0001. C-D) LC-HRMS metabolic profiling of DAOY scramble (●) and sip73*1 cells (▲). PCA score 
plots of the first two components, PC1 and PC2. The data were normalized to median fold change and pareto 
scale. C) Positive ionization mode (R2X=0.602 and Q2=0.137). D) Negative ionization mode (R2X=0.761 and 
Q2=0.355). E) List of the affected metabolites after p73KD in DAOY cells. 1Confidently identified metabolites, 
identification was based on retention time, exact mass and fragmentation as compared to an analytical standard 
that was analyzed under the same conditions. 2Putatively annotated metabolites, annotation was based on exact 
mass and fragmentation as compared to available reference spectra. 
Figure 4. p73 is a marker of glutamine addiction in MB. A) DAOY and UW228-2 cells were cultured for 24h 
under normal medium, glucose (Glc starv), glutamine (Gln starv) and serine/glycine (Ser/Gly starv) starvation 
condition. DAOY and UW228-2 cells were collected and cell number were determined. (n=3); Data are 
represented as mean±SD.**P<0.001,***P<0.0001. B) Representative image of DAOY cells under normal 
medium, Glc starv, Gln starv and Ser/Gly starv for 15h. Cells were stained with the proliferation marker EdU 
(green) and nuclear marker DAPI (blue). C) Histogram shows mean fluorescence intensities of EdU in DAOY 




as mean±SD,***P<0.0001. D) DAOY and UW228-2 cells were cultured for 24h under normal medium, glucose 
(Glc starv), glutamine (Gln starv) and serine/glycine (Ser/Gly starv) starvation condition. DAOY and UW228-2 
cells were collected and ATP levels were determined. (n=3); Data were mean±SD.**P<0.001,***P<0.0001. E) 
DAOY cells were cultured for 24h under normal medium, Glc starv, Gln starv and Ser/Gly starv. Next, cells were 
collected and a western blot of lysed cells was performed against p73. GAPDH was used as a loading control. 
F) DAOY cells were cultured for 20h under normal medium, Glc starv, Gln starv and Ser/Gly starv. Apoptosis 
was measured with Annexin V-FITC and PI for flow cytometry analysis. Images are representative of at least 
three independent experiments. G) DAOY, UW228-2 and ICb-1299 cells were cultured for 20h under normal 
medium, Gln starv and Gln starv plus 10M MG132. Apoptosis was measured with Annexin V-FITC and PI for 
flow cytometry analyse, (n=3). Data are represented as mean±SD.**P<0.001,***P<0.0001. 
Figure 5. Co-treatment of cisplatin plus glutamine starvation induces a synergic apoptotic effect in MB. 
A) DAOY cells were cultured for 18h under normal medium or Gln-starv with or without etoposide or cisplatin. 
Etoposide (+:6.8nM;++:13.6nM), cisplatin (+:16.6nM;++:33.3nM). Apoptosis was measured with Annexin V-
FITC and PI for flow cytometry analysis.(n=3). Data are represented as mean±SD.**P<0.001,***P<0.0001. B) 
Histogram shows mean fluorescence intensities of EdU in ICb-1299 cells under control medium, Gln-starv or 
4M compound 968, with or without cisplatin 16.6nM for 18h. C-D) DAOY cells were infected with an empty 
vector or with shRNA p73sKD*3 and p73sKD*5. Cells were incubated for 36h under normal medium, Gln-starv 
or Gln-starv plus cisplatin 16.6nM. Apoptosis was measured with Annexin V-FITC and PI by flow cytometry (C) 
or ATP levels (D) (n=3). Data are represented as mean±SD.**P<0.001,***P<0.0001. E) Apoptosis was 
determined in DAOY, ICb-1299, m137 and UW228-2 cells. Cell were treated with cisplatin 16.6nM, Gln-starv, 
Gln-starv plus cisplatin 16.6nM DON 0.9mM or DON plus cisplatin 16.6nM. The cells were collected and stained 
with Annexin V-FITC and PI for flow cytometry analysis (n=3). Data were mean±SD. *P<0.01,***P<0.0001. 
Figure 6. Glutamine starvation induces ROS and DNA damage in MB. A) DAOY and UW228-2 cells were 
cultured for 12h under normal medium, Glc starv, Gln starv and Ser/Gly starv. Cells were incubated with 
H2DCFDA probe, an indicator for ROS. B) DAOY cells were cultured for 12h under normal medium, Gln starv 
or Gln starv plus 0.1 M N-acetyl cysteine (NAC). Cells were incubated with H2DCFDA and analysed by FACS. 
C-D) DAOY cells were cultured under normal medium, Glc starv, Gln starv or Ser/Gly starv for 20h. Also, DAOY 
cells were incubated with Glut starv plus cisplatin for 10h. C) Representative image of DAOY cells stained with 
the DNA damage marker -H2AX (green) and nuclear marker DAPI (blue). Size bar=20μm. D) Histogram shows 
mean fluorescence intensities of EdU in DAOY cells (n=3), data are represented as mean±SD,***P<0.0001. E-
F) DAOY and UW228-2 cells were cultured for 24h under normal medium, Glc starv, Gln starv or Ser/Gly starv. 
E) Reduced and oxidized glutathione ratio was measured by using the GSH/GSSG-Glo assay kit. F) Cells were 
collect and NADH absorbance was determined at 340nm by FACS analysis.  
Figure 7. Glutamine restriction diet induces a significant improved survival in an orthotopic MB 
xenograft model. A-B) NOD-SCID mice were treated for 4 months with control diet or Gln-restriction diet. A) 
Glutamine, glutamate and serine levels were determined by ion-exchange chromatography in the cerebellum. 
B) Glutamine level was determined by ion-exchange chromatography in the CSF (n=5). Data are represented 
as mean±SD. **P<0.001,***P<0.0001. C-D) ICb-1299 human primary cells were injected in the cerebellum of 
new-born NOD-SCID mice and mice were divided into control diet (n=7), control diet + 2 doses cisplatin (n=11), 
control diet + 3 doses cisplatin (n=9), Gln-restriction diet (n=9), Gln-restriction diet + 2 doses cisplatin (n=8) or 
Gln-restriction diet + 3 doses cisplatin (n=7). C) Survival of mice is plotted over time, log-rank test. D) Histology 
of the MB tumors under control diet with 2 or 3 doses cisplatin or under Gln-restriction diet with 2 or 3 doses 
cisplatin, representative bright field images are shown for Ki-67 and cleaved caspase-3. Quantification is shown 
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control 9.22 ± 0.9 10
4
100 1.05
sip73*1 5.87 ± 0.6 10
4
63.66 1.1
sip73*2 3.91 ± 0.7 10
4
42.4 1.4
control 1.14 ± 0.2 10
6
100 1
sip73*2 0.55 ± 0.4 10
6
48.24 1.2
control 1.32 ± 0.2 10
6
100 1
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Serine 1163.4 ± 25 5465.1 ± 32 
Glycine 1450.5± 54  3237.2 ± 73 
Ornithine 173.3 ± 20 590.7 ± 12 
Proline 113.9 ± 21 163.2 ± 4 
Glutamate 1391.1 ± 64 116.3 ± 8 
Glutamine 2985.1 ± 42 0.0 ± 0 
Arginine 1133.7 ± 36 779.0 ± 8 
Taurine 29.7 ± 5 5.0 ± 0 
Alanine 6242.6 ± 47 76.5 ± 6 
Valine 2742.6 ± 96 1255.8 ± 78 
Methionine 579.2 ± 18 279.1 ± 67 
Isoleucine 2386.1 ± 36 1097.7 ± 45 
Leucine 2495.1 ± 12 1190.7 ± 34 
Tyrosine 1331.7 ± 66 632.6 ± 82 
Phenylalanine 1381.2 ± 53 637.2 ± 35 
Lysine 2683.2 ± 69 1255.8 ± 29 
Threonine 2747.5 ± 33 1283.7 ± 26 
Citrulline 54.5 ± 3 50.0 ± 0 
Histidine 668.3 ± 45 623.3 ± 23 
Metabolite Fold change p-value Experimental m/z Substance class















Guanosine 2 2,13 ± 0,61 1,71610-5 [M-H]- 282.0817 Nucleoside








Uridine 1 1,58 ± 0,39 0,0012
[M-H]- 279.0372
[F]- 110.0218  
[F]- 152.0320
Nucleoside
5´-methylthioadenosine 2 2,40 ± 0,32 1,63810-16 [M+H]+ 298.0974 Nucleoside derivative
Choline 1 -1,82 ± 0,17 1,51410-13 [M+H]+ 104.1073 Choline
Phenylalanine 1 1,52 ± 0,41 0,0063 [M-H]- 164.0688 Amino acid
Indoleacetic acid 2 2,03 ± 0,30 3,33510-11 [M-H2O+H]
+ 176.0712 Organic acid
N-Formyl-L-Methionine 2 2,66 ± 0,88 0,0001 [M-H2O+H]
+ 160.0432 Methionine derivative
4-phosphopantothenoylcysteine 2 1,76 ± 0,45 0,0001 [M-H]- 401.0796 Organic acid
Pyruvic acid 1 1,99 ± 0,70 0,0014 [M+FA-H]- 133.0128 Organic acid
Malic acid 1 -1,15 ± 0,11 0,0006 [M-H2O-H]
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c o n tro l+ 2  d o s e s  c is p la t in
c o n tro l+ 3  d o s e s  c is p la t in
G ln + 2  d o s e s  c is p la tin
G ln + 3  d o s e s  c is p la tin
c o n tro l d ie t
G ln -re s tr ic tio n  d ie t
P value P value summary
Control diet vs Gln-restriction diet 0.024 *
Control+2 doses cisplatin vs Gln+2 doses cisplatin <0.0001 ****
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